PDS Biotechnology Corp Operating Leases, Rent Expense
PDS Biotechnology Corp (PDSB) reported Operating Leases, Rent Expense of $36.02 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-05-13
- PDS Biotechnology Corp operating leases, rent expense for the quarter ending 2021-03-31 was $36.02K, a 38.58% decline year-over-year.
- PDS Biotechnology Corp operating leases, rent expense for the quarter ending 2020-12-31 was $42.69K, a 21.44% decline year-over-year.
- PDS Biotechnology Corp operating leases, rent expense for the quarter ending 2020-09-30 was $35.70K, a 6.95% decline year-over-year.
- PDS Biotechnology Corp operating leases, rent expense for the quarter ending 2020-06-30 was $46.34K, a 306.46% increase year-over-year.
- PDS Biotechnology Corp operating leases, rent expense for fiscal 2020 was $183.37K, a 62.26% increase from fiscal 2019.
- PDS Biotechnology Corp operating leases, rent expense for fiscal 2019 was $113.01K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2021-03-31 | $36.02K 10-Q · filed 2021-05-13 | $78.71K derived: sum of 2 quarters · filed 2021-05-13 | $114.41K derived: sum of 3 quarters · filed 2021-05-13 | $160.75K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $42.69K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $78.39K derived: sum of 2 quarters · filed 2021-03-18 | $124.73K derived: sum of 3 quarters · filed 2021-03-18 | $183.37K 10-K · filed 2021-03-18 |
| 2020-09-30 | $35.70K 10-Q · filed 2020-11-13 | $82.04K derived: sum of 2 quarters · filed 2020-11-13 | $140.68K 10-Q · filed 2020-11-13 | $195.02K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $46.34K 10-Q · filed 2020-08-13 | $104.98K 10-Q · filed 2020-08-13 | $159.32K derived: sum of 3 quarters · filed 2021-05-13 | $197.69K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $58.64K 10-Q · filed 2021-05-13 | $112.98K derived: sum of 2 quarters · filed 2021-05-13 | $151.35K derived: sum of 3 quarters · filed 2021-05-13 | $162.75K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $54.34K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $92.71K derived: sum of 2 quarters · filed 2021-03-18 | $104.11K derived: sum of 3 quarters · filed 2021-03-18 | $113.01K 10-K · filed 2021-03-18 |
| 2019-09-30 | $38.37K 10-Q · filed 2020-11-13 | $49.77K derived: sum of 2 quarters · filed 2020-11-13 | $58.66K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $11.40K 10-Q · filed 2020-08-13 | $20.30K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $11.08K 10-Q · filed 2020-05-13 | |||
| 2018-09-30 | $15.64K 10-Q · filed 2019-11-07 | $31.29K derived: sum of 2 quarters · filed 2019-11-07 | $46.93K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $15.64K 10-Q · filed 2019-08-01 | $31.29K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $15.64K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |